Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTMAB-16 in Pulmonary Sarcoidosis (Phase 1b/2, MAD/PoC)
2022-502877-41-00Phase 2Withdrawn
- Sponsor
- Xentria
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of xtmab-16 in pulmonary sarcoidosis (4 arms), sponsored by Xentria. Primary endpoints: Part A: Safety - Rate of adverse events, Part A: Pharmacokinetics profile and 6 more. Planned start Aug 2023; status: withdrawn.
02
Drugs
xtmab-16
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on 2022-502877-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502877-41-00.